Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
8.48
Nov 13 • 3:59 PM ET Dollar change+0.02 Percentage change(0.24%)
Aftermarket Close
8.33
Aftermarket • 4:15 PM ET Dollar change-0.15 Percentage change(-1.77%)
Index
-
Market Cap
49.52M
Enterprise Value
43.73M
Income
6.23M
Sales
0.15M
Book/sh
8.88
Cash/sh
0.99
Employees
-
IPO
Jul 25, 1983
P/E
6.94
Forward P/E
-
PEG
-
P/S
330.15
P/B
0.96
P/C
8.55
P/FCF
-
EV/EBITDA
7.02
EV/Sales
291.55
Quick Ratio
245.27
Current Ratio
245.27
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
1.22
EPS next Y
-0.03
EPS next Q
-0.04
EPS this Y
-320.00%
EPS next Y
85.71%
EPS next 5Y
-
EPS past 3/5Y
13.20% -
Sales past 3/5Y
- -
EPS Y/Y TTM
234.88%
Sales Y/Y TTM
-85.48%
EPS Q/Q
-791.41%
Sales Q/Q
-93.80%
Earnings
-
EPS/Sales Surpr.
- -
Insider Own
49.20%
Insider Trans
0.00%
Inst Own
8.12%
Inst Trans
-0.32%
ROA
14.20%
ROE
14.24%
ROIC
12.02%
Gross Margin
-106.52%
Oper. Margin
4024.05%
Profit Margin
4021.89%
SMA20
-5.57%
SMA50
-16.13%
SMA200
-20.29%
Trades
Shs Outstand
5.84M
Shs Float
2.97M
52W High
14.76 -42.54%
52W Low
8.24 2.91%
Volatility
2.93% 3.87%
ATR (14)
0.39
RSI (14)
33.12
Beta
0.44
Rel Volume
0.76
Avg Volume
22.20K
Volume
16,806
Perf Week
0.36%
Perf Month
-16.86%
Perf Quarter
-16.89%
Perf Half Y
-21.12%
Perf YTD
-42.51%
Perf Year
-32.27%
Perf 3Y
1.56%
Perf 5Y
-22.91%
Perf 10Y
6.94%
Prev Close
8.46
Price
8.48
Change %
0.24%
Consensus
Strong Buy
Avg. Price Target
$20.00
Implied Upside
+135.8%
Analysts1incl. previous ratings
Rating Distribution1 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 16, 2019Initiated
AAscendiant Capital Markets
Buy$20+135.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Feldschuh Michael RichardChief Executive OfficerApr 08 '26Buy9.071,0009,070213,694Apr 10 01:54 PM
Michel Robert JChief Financial OfficerMar 31 '26Buy9.901,0009,90021,050Mar 31 06:28 PM
DAXOR Corporation is an innovative medical instrumentation and biotechnology company. DAXOR designed and developed the BVA-100 Blood Volume Analyzer. It is the first instrument approved by the FDA to provide rapid direct measurement of a patient's true blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. The BVA-100 is a semi-automated Blood Volume Analyzer. It is used in conjunction with a single use diagnostic kit. It is the first FDA-approved instrument to provide rapid direct measurement of a patient's blood volume.
ChairmanMr. Michael Richard Feldschuh
M.B.A.Mr. Robert J. Michel CPA
Chief Scientific Officer & DirectorMr. Jonathan Adam Feldschuh
M.B.A.Dr. John Lynn Jefferies FACC
Vice President of Development & OperationsMs. Linda Cooper